Wyniki kolejnych badań uzasadniają stosowanie w 1 i 2 stadium choroby molnupirawiru lub kasiriwimabu/imdewimabu, a w stadium 3 baricytynibu2-5. Zaprzestano natomiast rekomendowania osocza ozdrowieńców ze względu na negatywne wyniki badań6,7. Ze względu na brak dowodów naukowych na skuteczność podtrzymano nie rekomendowanie do stosowania w COVID-19 leków takich jak: lopinawir/rytonawir, chlorochina, hydrochlorochina, azytromycyna, fawipirawir, amantadyna, oseltamiwir czy iwermektyna.
Piśmiennictwo:
1. Flisiak R, Horban A, Jaroszewicz J, Kozielewicz D, Mastalerz-Migas A, Owczuk R, Parczewski M, Pawłowska M, Piekarska A, Simon K, Tomasiewicz K, Zarębska-Michaluk D. Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. Pol Arch Intern Med 2021; 131 (5): 487-496, doi:10.20452/pamw.15972. Mahase E. Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ. 2021 Oct 4;375:n2422. doi: 10.1136/bmj.n2422.
3. Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Loftis AJ, Alabanza P, Lipansky F, Painter WP. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv [Preprint]. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639.
4. Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021 Aug 31:S2213-2600(21)00331-3. doi: 10.1016/S2213-2600(21)00331-3. Epub ahead of print.
5. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, Rofail D, Hussein M, Im J, Atmodjo DY, Perry C, Pan C, Mahmood A, Hosain R, Davis JD, Turner KC, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Roque-Guerrero L, Acloque G, Aazami H, Cannon K, Simón-Campos JA, Bocchini JA, Kowal B, DiCioccio AT, Soo Y, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD; Trial Investigators. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med. 2021 Sep 29:NEJMoa2108163. doi: 10.1056/NEJMoa2108163. Epub ahead of print.
6. Snow TAC, Saleem N, Ambler G, Nastouli E, McCoy LE, Singer M, Arulkumaran N. Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regression. Br J Anaesth. 2021 Aug 30:S0007-0912(21)00546-8. doi: 10.1016/j.bja.2021.07.033. Epub ahead of print.
7. Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, Smith ER, Haber NA, Khanna N, Moher D, Goodman SN, Ioannidis JPA, Hemkens LG. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA. 2021 Mar 23;325(12):1185-1195. doi: 10.1001/jama.2021.2747.
8. Lagevrio - Summary of Product Characteristics, https://www.gov.uk/government/publications/regulatory-approval-of-lagevrio-molnupiravir/summary-of-product-characteristics-for-lagevrio
9. FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19, https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19
10. Veklury – charakterystyka produktu leczniczego, https://www.ema.europa.eu/en/documents/product-information/veklury-epar-product-information_pl.pdf
11. RoActemra – charakterystyka produktu leczniczego, https://www.roche.pl/content/dam/rochexx/roche-pl/roche_poland_rwd/pl_PL/documents/SmPC/roactemra_koncentrat.pdf
12. Olumiant - charakterystyka produktu leczniczego, https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_pl.pdf
